Earlier investigations demonstrate that CD40 stimulation, in addition to activating tumor-associated immunosuppressive macrophages and T cells and inhibiting tumor progression (80, 81), also remodels the TME and heightens the tumor’s responsiveness to checkpoint blockade therapies in various types of cancer (82, 83). The gene discussed is CD40; the disease is cancer.